 Home > Medical News > Latest Medical News > German Merck obtains exclusive global development rights for xevinapant

German Merck obtains exclusive global development rights for xevinapant

 Last Update: 2021-03-23
 Source: Internet
 Author: User

Tags

development engineering

fractionation

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Source: Immediate Medicine News

On March 1, 2021, Debiopharm announced that it has signed an exclusive license agreement for the development and commercialization of xevinapant (Debio1143) with German Merck (Merck KGaA).

According to the terms of the license agreement, Merck, Germany, has obtained the exclusive global development and commercialization rights of xevinapant, and will co-fund the ongoing Phase 3 registered TrilynX study with Debiopharm, which aims to evaluate the deterministic standard of chemoradiation therapy (chemoradiation therapy, CRT) based on the efficacy and safety of xevinapant and placebo.

The results of a previously reported randomized, double-blind phase 2 clinical study showed that the addition of xevinapant to the standard treatment of CRT improved the local area control rate by 21% at 18 months, which was statistically significant and reached the primary endpoint.

Squamous cell carcinoma of the head and neck is the sixth most common type of cancer in the world, and more than half of the patients have locally advanced tumors at the time of diagnosis.

Mr.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

Reference materials:

[1] Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.